High- vs low-dose propofol to reduce nausea after coronary bypass
The Effect of Propofol Infusion on Postoperative Nausea and Vomiting in Cardiac Surgery: A Prospective Observational Cohort Study
We will see if giving higher-dose propofol during coronary artery bypass surgery reduces postoperative nausea and vomiting in adults having elective CABG.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Istanbul University - Cerrahpasa Academic / other |
| Locations | 1 site (Istanbul, Outside of the US) |
| Trial ID | NCT07386379 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational cohort comparing routinely administered high‑dose versus low‑dose propofol infusions in adults undergoing elective on‑pump CABG at Istanbul University‑Cerrahpaşa. Investigators will record PONV incidence and severity during the first 24 hours after surgery and track the need for antiemetic therapy in the ICU. The study will also measure how well the Apfel and Koivuranta risk scores predict PONV in this cardiac surgery population. Standardized anesthesia with TIVA using propofol, BIS monitoring, and predefined inclusion/exclusion criteria will be applied at a single center over a defined time window.
Who should consider this trial
Good fit: Adults (≥18 years) with ASA physical status III scheduled for elective on‑pump CABG at Istanbul University‑Cerrahpaşa between November 2025 and March 2026 who can give informed consent and meet the enrollment criteria.
Not a fit: Patients with recent gastrointestinal or central nervous system disorders, chronic opioid use, advanced hepatic or renal disease, LVEF <40%, off‑pump or emergency procedures, or those unable to be weaned from ventilation within 12 hours are unlikely to benefit from the study findings.
Why it matters
Potential benefit: If successful, the findings could reduce nausea and vomiting after CABG and lower reliance on antiemetic medications in the ICU.
How similar studies have performed: Previous trials show propofol-based TIVA reduces PONV versus inhalational anesthesia, but evidence for a clear dose-dependent antiemetic effect in cardiac surgery patients is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria Age ≥ 18 years ASA physical status III Elective coronary artery bypass grafting (CABG) Surgery performed at Istanbul University-Cerrahpaşa, Cardiology Institute between November 2025 and March 2026 Exclusion Criteria Gastrointestinal or central nervous system disorders within the past 3 months Cochlear disorders associated with nausea and vomiting Chronic opioid use Advanced hepatic or renal disease Alcohol or substance abuse Left ventricular ejection fraction \< 40% Inability to be weaned from mechanical ventilation within 12 hours postoperatively Postoperative morphine administration in the intensive care unit Combined cardiac procedures (e.g., valve surgery) Off-pump surgery Emergency surgery Reoperation due to bleeding or other complications Refusal to participate
Where this trial is running
Istanbul, Outside of the US
- Yasemin Ozsahin — Istanbul, Outside of the US, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Yasemin Ozsahin
- Email: yasemin.ozsahin@iuc.edu.tr
- Phone: +90 536 925 67 21
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.